Close

Catabasis Pharma (CATB) Surges 50% on Deal with Serepta (SRPT)

Go back to Catabasis Pharma (CATB) Surges 50% on Deal with Serepta (SRPT)

Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy

September 29, 2016 8:00 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage biopharmaceutical company (Catabasis), and Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage developer... More